High prices for novel speciality drugs are an increasingly topical and urgent issue on the agenda of political decision makers and the international health care community. Governments, and health insurers struggle to find the budgets needed to provide coverage for these expensive medicines.
The Belgian Healthcare Knowledge Centre (KCE) and their Dutch counterpart Zorginstituut Nederland decided to initiate a consultative process to explore potential solutions to this complex societal challenge. The aim of the project was to elaborate future scenarios and to explore more sustainable ways to ensure patient access to safe and effective drugs, while providing strong incentives for innovation and focussing on real health needs.
The scenario project benefited from the active contribution of a carefully selected group of experts and stakeholders from Europe and North America, including patient representatives, industry leaders, academics, regulators, payers, and government representatives. The resulting report (in press) presents four coherent scenarios, developed on the basis of in-depth interviews of the experts, followed by two 2-day deliberative workshops in Amsterdam, in March and April 2016. shiftN was responsible for the data gathering, interviews, design and facilitation of the scenario workshops, and the writing of the final report.